Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Item

http://www.wikidata.org/entity/Q35567212

Q35567212

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Immunobiology and immunotherapy in genitourinary malignancies Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?A Perspective of Immunotherapy for Prostate Cancer New drugs in prostate cancer The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements Cancer immunotherapy: the beginning of the end of cancer?Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Antagonists of PD-1 and PD-L1 in Cancer Treatment Immune Infiltration and Prostate Cancer Immune Checkpoint Blockade in Cancer Therapy From bench to bedside: immunotherapy for prostate cancer Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Immune regulation of bone metastasis The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Targeting the adaptive molecular landscape of castration-resistant prostate cancer Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies Immunotherapy in metastatic prostate cancer Focus on Nivolumab in NSCLC Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Immune checkpoint blockade: a common denominator approach to cancer therapy Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.Current clinical trials testing the combination of immunotherapy with radiotherapy.Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Immunotherapy in genitourinary malignancies.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment News Feature: Radiation redux Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer

P2860

Q26738443-7158D632-F61D-4B7A-B227-2EC0ACEA2164 Q26738668-A68AFDA6-58C5-4F85-800E-818CC9A1041D Q26740601-C1857756-49AB-4449-B75C-24796B613F0F Q26741277-3CB063A7-C71D-4C4E-82E2-B1C7C57517C8 Q26745948-0019B755-8BC2-4D53-8D58-8A54622985D4 Q26750672-B2596CE9-9A55-4D64-9064-145F1B1B4062 Q26752277-D82BC027-9819-4DAD-825B-EBF435073945 Q26766638-C17A4C42-F52C-446C-B787-7527592D229D Q26774934-9552A2A7-206A-4548-BB94-BB26552A2F3E Q26775034-29A4D8F3-38A1-4E75-B178-4B807334784C Q26779221-68ABC328-EF8E-40F7-9D99-725867C6B638 Q26796311-0BAC237D-29D4-4ED1-9E9A-CA4B6253C01D Q26798412-9AD19B85-41D0-41D1-8DB4-F5D6C8980871 Q26830509-1215E874-E2CD-4B8F-A97D-84EBBA7C35B3 Q26864390-1FFCEF62-8ED0-46A7-B426-158D15C0649C Q26995499-F476D4CC-7287-4A92-BBA0-3B74501F2987 Q26996518-DD5EE85B-D826-4AD6-A48B-D27B0F1B2546 Q27005871-F8D1E506-AC6F-463C-9440-B5C034BAF6FB Q27022789-3E3C7ED5-7E6B-47B6-A4BF-A4FB05746C8F Q27022821-DE0777D5-EB82-425B-A07D-AD1EF8F6A4C8 Q28066199-834F038C-923C-4625-B3DD-72022BE07E0A Q28069864-3742404C-A8DA-45EB-8393-E29E54B6CD79 Q28072007-0909EE25-F0A5-4E5B-8F9F-E96ECAB0223B Q28072081-DEF8CF9C-730F-4FA9-AE74-6A72A38E49B4 Q28073759-49390862-355B-4312-AD63-368F359DAE1C Q28075965-A4586325-D850-4E9C-86C1-D9B1FA2C5D3C Q28083981-881A9CEC-ABA4-4226-A0CE-166C1AC12753 Q30235360-27E87BF4-01E7-49A4-BE07-FDF1488B66F8 Q30276874-D41D79EF-FA17-4FF4-8DD4-17F4FCB28DF0 Q30356447-E61ACB16-74B1-471A-9C3A-203EFF7F7DCA Q31171172-0D6F412D-4765-4C8C-AD57-C5A95AC69A10 Q33440805-B0A58861-C131-41F0-88B8-23C2EA38B479 Q33564645-BA79E358-6973-44BE-9771-313D235F9B60 Q33593800-3B47806D-5DD6-452A-81DE-86A69DE36998 Q33607108-6EE13ECA-2853-4E00-AFA2-137558592466 Q33645624-CB167EC5-42EA-4E23-B68D-D08BEAE4872F Q33653836-29C9B843-3707-4DC3-9E37-CE069F27E96A Q33718182-977D919F-ABE5-4FB3-B13D-7F85D0DEA1E9 Q33847819-9D30B471-2240-4EDF-B7E6-5E4C4FA0C2A2 Q33873633-0323BD0E-E84A-4BC5-90FB-3CDD4E1A6D44

P2860

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Item

http://www.wikidata.org/entity/Q35567212

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Ipilimumab versus placebo afte ...... , double-blind, phase 3 trial.

@ast

Ipilimumab versus placebo afte ...... , double-blind, phase 3 trial.

@en

type

Item

label

Ipilimumab versus placebo afte ...... , double-blind, phase 3 trial.

@ast

Ipilimumab versus placebo afte ...... , double-blind, phase 3 trial.

@en

prefLabel

Ipilimumab versus placebo afte ...... , double-blind, phase 3 trial.

@ast

Ipilimumab versus placebo afte ...... , double-blind, phase 3 trial.

@en

P1476

Ipilimumab versus placebo afte ...... , double-blind, phase 3 trial.

@en

P2093

Alberto Bossi

http://www.w3.org/2001/XMLSchema#string

Alfons J M van den Eertwegh

http://www.w3.org/2001/XMLSchema#string

Andries M Bergman

http://www.w3.org/2001/XMLSchema#string

CA184-043 Investigators

http://www.w3.org/2001/XMLSchema#string

Charles G Drake

http://www.w3.org/2001/XMLSchema#string

Christopher Logothetis

http://www.w3.org/2001/XMLSchema#string

David Liu

http://www.w3.org/2001/XMLSchema#string

Ernesto Korbenfeld

http://www.w3.org/2001/XMLSchema#string

Eugene D Kwon

http://www.w3.org/2001/XMLSchema#string

Fabio A Franke

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Prostate cancer: ESMO Consensus Conference Guidelines 2012

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

P304

700-712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(14)70189-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24831977

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

Ipilimumaab

placebo

phase III clinical trial

multicenter trial

chemotherapy

P932

4418935

http://www.w3.org/2001/XMLSchema#string

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

about

P2860

P2860

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932